James Cook University Hospital

The government has announced a fund of £250m to provide another 5,000 NHS England hospital beds this winter, to relieve pressure on hospitals and reduce waiting times. As part of the NHS Urgent and Emergency Care Recovery Plan, over 30 NHS organisations across England will benefit from the investment in urgent and emergency care services. Over 900 new hospital beds, including 60 intermediate care beds, should be ready by January 2024 to increase capacity on hospital wards and A&E to 100,000. The scheme will also improve assessment spaces and cubicles in A&E. Health and social care secretary, Steve Barclay, said: “Creating additional hospital capacity will support staff to provide the best possible care and treat patients more quickly, helping us to improve waiting times and cut waiting lists – one of the government’s top five priorities.” Trusts including Hull Royal Infirmary, James Cook University Hospital and Worthing Hospital will develop or expand urgent treatment centres to treat patients more quickly. Others will also use the funding to develop or expand same-day emergency care services to help assess, diagnose and treat patients more quickly. At Peterborough City Hospital, £12.5m will be used to provide 72 new hospital beds and Northwick Park Hospital, London will use the £22.6m investment to create a 32-bed modular acute medical ward to increase the hospitals capacity this winter. In response to the announcement, chief analyst at The King’s Fund, Siva Anandaciva, said their research found that “the UK has relatively few hospital beds, with 2.5 beds per 1,000 people compared to an average of 3.2, placing the UK second to last out of 19 peer countries. “Last year, (…) the direct cost of each delayed discharge was nearly £400 per night, and this added up to £1.9 billion spent over 2022/23. This shows that early investment for planning goes a long way to make better use of the NHS’s resources and improve care for patients.” The plan will also include a commitment for 800 new ambulances, including specialist mental health ambulances to improve response times this winter. Earlier this month, the NHS announced that its virtual ward programme would be expanded to children, with virtual ward bed numbers predicted to hit 10,000 by the autumn.

CAMBRIDGE, Md., Dec. 15, 2022 /PRNewswire/ -- South Tees Hospitals NHS Foundation Trust, one of the most active research organizations in the northeast of England, has joined the TriNetX network to increase its visibility to commercial partners for additional research opportunities. "We recently merged the R&D departments from two acute NHS Trusts into a Tees Valley Research Alliance (TVRA), to improve efficiencies and share study opportunities so that more patients can benefit from research participation," said Jane Greenaway, Associate Director, TVRA. "Part of our strategic objective is to make ourselves more visible as a site to commercial partners and TriNetX offered the ideal solution to help us achieve this goal on a global scale." South Tees Hospitals NHS Foundation Trust recruits more than 3,500 patients into research studies in 23 clinical specialties each year and has significant experience in launching and managing grant-funded, Trust-sponsored research projects. They are a key site in the delivery of vaccine studies in the UK. The organization serves nearly 750,000 patients across Teesside in the northeast of England and provides wider specialist services to a population of 1.5 million. "We've been developing the partnership with TriNetX over a number of years and have been so impressed by the support, knowledge, and professionalism from the organization," said Greenaway. "Connecting with their global data platform for real-world evaluations is very exciting and we can't wait to make our researchers aware of the platform's capabilities." TriNetX is the largest and fastest growing collaborative research network comprised of healthcare organizations and life sciences companies driving real-world research to accelerate the development of new therapies. TriNetX puts the power of real-world data into the hands of its worldwide community to improve protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. "South Tees Hospitals NHS Foundation Trust is extremely active in both commercial and investigator-initiated research across many disease areas," said Steve Lethbridge, Senior Vice President of Global Healthcare Partnerships at TriNetX. "We are pleased to welcome South Tees Hospitals as a TriNetX member and to help them achieve their goal of increasing study opportunities and capabilities for all of their researchers and patients." About TriNetX, LLC TriNetX is a global network of healthcare organizations and life sciences companies driving real-world research to accelerate the development of new therapies. Through its self-service, HIPAA, GDPR, and LGPD-compliant platform of federated EHR, datasets, and consulting partnerships, TriNetX puts the power of real-world data into the hands of its worldwide community to improve protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. For more information, visit TriNetX at or follow @TriNetX on Twitter. About South Tees Hospitals NHS Foundation Trust South Tees Hospitals NHS Foundation Trust is a regional major trauma center and tertiary hospital provider in northeast England, serving a population of 1.5 million. It consists of two hospital sites–The James Cook University Hospital in Middlesbrough, Friarage Hospital in Northallerton and multiple community hubs. The organization provides 37 different specialties delivering world-class services including cancer, cardiothoracic, orthopaedic, renal, cochlear implant, neurosciences, gynaecology, vascular and urology care for patients across the region and beyond. For more information, visit South Tees Hospitals NHS Foundation Trust at Media Contacts TriNetX, LLC Bill Stetson (857) 285-6038 [email protected] South Tees Hospitals NHS Foundation Trust 01642 854343 [email protected] SOURCE TriNetX

SUNNYVALE, Calif., Nov. 17, 2022 /PRNewswire/ -- EBR Systems, Inc. (ASX: "EBR", "EBR Systems", or the "Company"), developer of the world's only wireless cardiac pacing system for heart failure, is pleased to announce that the Company's WiSE® technology will be featured at the 15th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in Singapore from the 18th to the 20th of November. The APHRS is a leading non-profit organisation that represents medical, allied health, and science professionals specialising in cardiac rhythm disorders in the Asia-Pacific region. The annual conference is a premier event featuring industry workshops and a core scientific programme delivered by international and regional speakers. Five abstracts featuring WiSE® have been accepted for presentations, highlighting the technology's position at the forefront of innovation in the cardiac rhythm management landscape. Abstracts featuring WiSE® at the APHRS scientific session include the following: Does Cardiac Resynchronisation Using WiSE® - CRT Leadless Pacing Result in Greater QRS Shortening Than Conventional Resynchronisation? - Dr Simon James (James Cook University Hospital, UK) Feasibility of Totally Leadless CRT with Leadless Pacemaker and Leadless LV Endocardial Pacing System - Prof Pascal Defaye (Grenoble Alpes University Hospital, France) Leadless Left Bundle Branch Area Pacing: A Feasibility Study - Dr Mark Elliott (St Thomas' Hospital, UK) The Effect of Electrode Location on Battery Longevity During Leadless LV Endocardial Pacing - Dr Mark Elliott (St Thomas' Hospital, UK) The First Totally Leadless CRT System in the US - Dr Dinesh Sharma (NCH Heart Institute, USA) John McCutcheon, EBR Systems' President & Chief Executive Officer said: "We are excited to see our WiSE® System continue to feature in leading conferences around the world. The abstracts presented at this scientific session strengthen the body of data supporting WiSE® while promoting our technology to a wide audience including industry partners and the broader scientific community." About EBR Systems (ASX: EBR) Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications. EBR Systems' WiSE® Technology EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US. SOURCE EBR Systems